According to Spyryx Biosciences, Cystic Fibrosis Foundation Therapeutics (CFFT) will increase a development award to Spyryx to provide a total of up to $5 million. The company said that it plans to use the funds for its HOPE-1 Phase 2 study of SPX-101, an inhaled SPLUNC1-derived peptide, in CF patients.
Earlier this year, Spyryx announced positive top line data from a Phase 1 study of SPX-101 and said that it planned to conduct a Phase 2 study based on those results.
Spyryx Chief Medical Officer Alistair Wheeler commented, “The data from the Phase 1 study validate the safety of SPX-101’s novel mechanism of action via the internalization of epithelial sodium channels with a small, inhaled peptide. Our ability to deliver the peptide without significant systemic exposure or any reports of hyperkalemia are key to advancing the program into a meaningful efficacy study. We are thrilled that CFFT has generously provided additional funding to support our Phase 2 study. We remain committed to bringing this new potential treatment to people living with CF and look forward to further evaluating this innovative peptide.”
Read the Spyryx Biosciences press release.
